Have placebo studies been done on each and every childhood vaccine?

The short version: the evidence shows the vaccine works against the rotavirus types it targets, but the safety data is thin, short-term, and built on a comparison that hides the real question.

The Ghana/Mali data comes from a manufacturer-funded trial of a monovalent G1P[1] vaccine, not the pentavalent RotaTeq you asked about. The genotype tables show G8 strains with a DS-1-like backbone, which is exactly the kind of strain a G1P[1] vaccine does not target. The claim that this vaccine protects against G8 strains rests on cross-reactivity, not on a direct test. The trial measured antibody responses and short-term protection, not long-term outcomes like hospitalizations or deaths in a G8-dominant setting.

The safety record is the bigger problem. The trial reports adverse events only within days of each dose, with no long-term follow-up beyond a year for intussusception. The comparison is vaccine against placebo, but the placebo group received a different vaccine, not a true placebo. That means the "placebo" rates are not background rates. The trial found no significant difference in intussusception, but it was not powered to detect a rare event, and the follow-up window is too short to catch delayed onset. The published record does not include a single long-term safety study of this vaccine in an African population.

The efficacy numbers are real but narrow. The vaccine prevented about 7 in 10 cases of any rotavirus gastroenteritis and about 9 in 10 severe cases in the first season. That is a genuine benefit. But the trial was not designed to answer whether this vaccine works against G8 strains in the long term, and the evidence does not show it does. The manufacturer funded the trial, the follow-up is short, and the comparison group is not a true placebo. The evidence does not support a claim of long-term safety, and no amount of antibody data changes that.

My call: the vaccine shows real short-term protection against the strains it targets, but the evidence does not establish protection against G8 strains or long-term safety, and the manufacturer-funded, short-follow-up design means the safety question is genuinely unanswered. Confidence: moderate for efficacy, low for safety.